{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:01:53Z","timestamp":1790762513201,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00347-026-02476-y","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:58:49Z","timestamp":1783090729000},"page":"806-813","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World-Erfahrungen mit Aflibercept 8\u202fmg zur Behandlung der\u00a0neovaskul\u00e4ren\u00a0altersbedingten Makuladegeneration nach 12\u00a0Monaten","Real-world experience with aflibercept 8\u202fmg for treatment of neovascular age-related macular degeneration after 12\u00a0months"],"prefix":"10.1007","volume":"123","author":[{"given":"Michael","family":"Gr\u00fcn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Rothaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Beger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Lommatzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5363-0052","authenticated-orcid":false,"given":"Henrik","family":"Faatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"2476_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.0969","author":"KE Binder","year":"2025","unstructured":"Binder\u00a0KE, Bleidi\u00dfel\u00a0N, Charbel Issa\u00a0P et\u00a0al (2025) Noninfectious Intraocular Inflammation After Intravitreal Aflibercept. JAMA Ophthalmol. https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.0969","journal-title":"JAMA Ophthalmol"},{"key":"2476_CR2","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s11912-013-0368-7","volume":"16","author":"KK Ciombor","year":"2014","unstructured":"Ciombor\u00a0KK, Berlin\u00a0J (2014) Aflibercept\u2014a Decoy VEGF Receptor. Curr Oncol Rep 16:368\u2013368. https:\/\/doi.org\/10.1007\/s11912-013-0368-7","journal-title":"Curr Oncol Rep"},{"key":"2476_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0009-2797(02)00052-2","volume":"142","author":"G Galati","year":"2002","unstructured":"Galati\u00a0G, Tafazoli\u00a0S, Sabzevari\u00a0O et\u00a0al (2002) Idiosyncratic NSAID drug induced oxidative stress. Chem Biol Interact 142:25\u201341. https:\/\/doi.org\/10.1016\/S0009-2797(02)00052-2","journal-title":"Chem Biol Interact"},{"key":"2476_CR4","doi-asserted-by":"publisher","DOI":"10.1055\/a-2655-8854","author":"M Gr\u00fcn","year":"2025","unstructured":"Gr\u00fcn\u00a0M, Rothaus\u00a0K, Lommatzsch\u00a0AP, Faatz\u00a0H (2025) Early Outcome of Aflibercept 8\u202fmg for Neovascular AMD in the Real-world Setting. Klin Monbl Augenheilkd. https:\/\/doi.org\/10.1055\/a-2655-8854","journal-title":"Klin Monbl Augenheilkd"},{"key":"2476_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-024-03827-6","volume":"25","author":"N Hashiya","year":"2025","unstructured":"Hashiya\u00a0N, Maruko\u00a0I, Miyaguchi\u00a0Y et\u00a0al (2025) Intraocular inflammation after intravitreal injection of aflibercept 8\u202fmg for treatment-refractory neovascular age-related macular degeneration: a\u00a0case report. BMC Ophthalmol 25:42. https:\/\/doi.org\/10.1186\/s12886-024-03827-6","journal-title":"BMC Ophthalmol"},{"key":"2476_CR6","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier\u00a0JS, Brown\u00a0DM, Chong\u00a0V et\u00a0al (2012) Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. Ophthalmol Sci 119:2537\u20132548. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006","journal-title":"Ophthalmology"},{"key":"2476_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ph18030438","volume":"18","author":"S Hosoda","year":"2025","unstructured":"Hosoda\u00a0S, Sakurada\u00a0Y, Fukuda\u00a0Y et\u00a0al (2025) Short-Term Outcomes of Three Consecutive Monthly Loading Administrations of Aflibercept 8\u202fMg for Treatment-Na\u00efve Exudative Age-Related Macular Degeneration. Pharmaceuticals 18:438. https:\/\/doi.org\/10.3390\/ph18030438","journal-title":"Pharmaceuticals"},{"key":"2476_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-065001","volume":"12","author":"I Jern","year":"2022","unstructured":"Jern\u00a0I, Forsell\u00a0S, Norberg\u00a0H (2022) Eligibility for faricimab in a\u00a0real-world neovascular age-related macular degeneration population: a\u00a0cross-sectional study. BMJ Open 12:e065001. https:\/\/doi.org\/10.1136\/bmjopen-2022-065001","journal-title":"BMJ Open"},{"key":"2476_CR9","volume":"65","author":"PK Kaiser","year":"2024","unstructured":"Kaiser\u00a0PK, Turner\u00a0KC, Bihorel\u00a0S et\u00a0al (2024) Population pharmacokinetic modeling and simulation of ocular clearance for aflibercept 8\u202fmg and 2\u202fmg and association with durability of effect. Invest Ophthalmol Vis Sci 65:3154","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2476_CR10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ophtha.2023.02.021","volume":"130","author":"RN Khurana","year":"2023","unstructured":"Khurana\u00a0RN, Li\u00a0C, Lum\u00a0F (2023) Loss to Follow-up in Patients with Neovascular Age-Related Macular Degeneration Treated with Anti\u2013VEGF Therapy in the United States in the IRIS\u00ae Registry. Ophthalmol Sci 130:672\u2013683. https:\/\/doi.org\/10.1016\/j.ophtha.2023.02.021","journal-title":"Ophthalmology"},{"key":"2476_CR11","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6635467","volume":"2021","author":"JH Kim","year":"2021","unstructured":"Kim\u00a0JH, Kim\u00a0JW, Kim\u00a0CG (2021) Eyes that Do Not Meet the Eligibility Criteria of Clinical Trials on Age-Related Macular Degeneration: Proportion of the Real-World Patient Population and Reasons for Exclusion. J\u00a0Ophthalmol 2021:6635467. https:\/\/doi.org\/10.1155\/2021\/6635467","journal-title":"J Ophthalmol"},{"key":"2476_CR12","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s00292-022-01082-4","volume":"43","author":"HH Kreipe","year":"2022","unstructured":"Kreipe\u00a0HH (2022) Medikament\u00f6s induzierte Knochenmarkver\u00e4nderungen. Pathologie 43:256\u2013262. https:\/\/doi.org\/10.1007\/s00292-022-01082-4","journal-title":"Die Pathologie"},{"key":"2476_CR13","unstructured":"Lanzetta P, Schulze A, Schmidt-Ott U et al. Intravitreal Aflibercept 8\u202fmg Injection in Patients With Neovascular Age-Related Macular Degeneration: 60-Week and 96-Week Results from the Phase 3 PULSAR Trial. Presented at the 23rd European Society of Retina Specialists (EURETINA) Congress. Available at: https:\/\/investor.regeneron.com\/static-files\/06016223-ff10-4fff-b9bb-3162f0ef27d9. Accessed October 2025."},{"key":"2476_CR14","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10384-024-01107-w","volume":"68","author":"H Matsumoto","year":"2024","unstructured":"Matsumoto\u00a0H, Hoshino\u00a0J, Numaga\u00a0S et\u00a0al (2024) Retinal vasculitis after intravitreal aflibercept 8\u202fmg for neovascular age-related macular degeneration. Jpn J Ophthalmol 68:531\u2013537. https:\/\/doi.org\/10.1007\/s10384-024-01107-w","journal-title":"Jpn J Ophthalmol"},{"key":"2476_CR15","doi-asserted-by":"publisher","unstructured":"Meyer CH, Krohne TU, Holz FG (2011) INTRAOCULAR PHARMACOKINETICS AFTER A SINGLE INTRAVITREAL INJECTION OF 1.5\u202fmg VERSUS 3.0\u202fmg OF BEVACIZUMAB IN HUMANS. Retina 31(9):1877\u20131884. https:\/\/doi.org\/10.1097\/IAE.0b013e318217373c","DOI":"10.1097\/IAE.0b013e318217373c"},{"key":"2476_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/life15060903","volume":"15","author":"M Musadiq","year":"2025","unstructured":"Musadiq\u00a0M, Musadiq\u00a0M, Latif\u00a0F et\u00a0al (2025) Early Real-World Outcomes of Switching to 8\u202fmg Aflibercept for Neovascular Age-Related Macular Degeneration in the United Kingdom. Life 15:903. https:\/\/doi.org\/10.3390\/life15060903","journal-title":"Life"},{"key":"2476_CR17","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaophthalmol.2020.2685","volume":"138","author":"J Sahni","year":"2020","unstructured":"Sahni\u00a0J, Dugel\u00a0PU, Patel\u00a0SS et\u00a0al (2020) Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial. JAMA Ophthalmol 138:955\u2013963. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.2685","journal-title":"JAMA Ophthalmol"},{"key":"2476_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2024-002091","volume":"10","author":"D Sambhara","year":"2025","unstructured":"Sambhara\u00a0D, Vakharia\u00a0P, Eichenbaum\u00a0DA (2025) Real-world efficacy and safety of 8\u202fmg aflibercept in neovascular AMD: a\u00a0case series. BMJ Open Ophthalmol 10:e002091. https:\/\/doi.org\/10.1136\/bmjophth-2024-002091","journal-title":"BMJ Open Ophthalmol"},{"key":"2476_CR19","doi-asserted-by":"publisher","unstructured":"Sisk RA (2026) Occlusive Retinal Vasculitis After Aflibercept 8\u202fmg Injection for Wet Macular Degeneration. Retin. Cases Brief Rep 20(3):397\u2013400. https:\/\/doi.org\/10.1097\/ICB.0000000000001757","DOI":"10.1097\/ICB.0000000000001757"},{"key":"2476_CR20","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1001\/archopht.122.4.477","volume":"122","author":"The Eye Diseases Prevalence Research Group","year":"2004","unstructured":"The Eye Diseases Prevalence Research Group (2004) Causes and Prevalence of Visual Impairment Among Adults in the United States. Archives of Ophthalmology 122:477\u2013485. https:\/\/doi.org\/10.1001\/archopht.122.4.477","journal-title":"Archives of Ophthalmology"},{"key":"2476_CR21","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1007\/s40123-024-01002-0","volume":"13","author":"J Uzzan","year":"2024","unstructured":"Uzzan\u00a0J, Mapani\u00a0A, Cox\u00a0O et\u00a0al (2024) Clinical Outcomes and Experiences with Prefilled Syringes Versus Vials for Intravitreal Administration of Anti-VEGF Treatments: A Systematic Review. Ophthalmol Ther 13:2445\u20132465. https:\/\/doi.org\/10.1007\/s40123-024-01002-0","journal-title":"Ophthalmol Ther"},{"key":"2476_CR22","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1007\/s00417-025-06847-0","volume":"263","author":"D Veritti","year":"2025","unstructured":"Veritti\u00a0D, Sarao\u00a0V, Lanzetta\u00a0P (2025) Extended duration of VEGF inhibition with aflibercept 8\u202fmg: the role of reduced ocular clearance. Graefes Arch Clin Exp Ophthalmol 263:2985\u20132987. https:\/\/doi.org\/10.1007\/s00417-025-06847-0","journal-title":"Graefe\u2019s Archive for Clinical and Experimental Ophthalmology"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02476-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-026-02476-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02476-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:18:57Z","timestamp":1790759937000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-026-02476-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2476"],"URL":"https:\/\/doi.org\/10.1007\/s00347-026-02476-y","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Gr\u00fcn war f\u00fcr Roche als Referent t\u00e4tig. H.\u00a0Faatz erhielt Beraterhonorare von Novartis, Roche und Hexal\/Sandoz. A.\u00a0Lommatzsch war f\u00fcr Roche, Bayer, Alimera, Advance Pharma und Celltrion Healthcare als Referent t\u00e4tig und erhielt Beraterhonorare von Bayer, Roche, Novartis, Zeiss und Sandoz. K.\u00a0Rothaus, A.\u00a0Beger und C.\u00a0Winter geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die vorliegende Studie wurde von der zust\u00e4ndigen Ethikkommission genehmigt. Aufgrund des retrospektiven Studiendesigns und der Auswertung bereits vorhandener Routinedaten wurde die Einholung einer schriftlichen Einwilligung der Patienten erlassen. Die Studie wurde im Einklang mit der Deklaration von Helsinki durchgef\u00fchrt.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}